Welcome to our dedicated page for CHARLES RIVER LABORATORIES INTERNATIONAL SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CHARLES RIVER LABORATORIES INTERNATIONAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CHARLES RIVER LABORATORIES INTERNATIONAL's regulatory disclosures and financial reporting.
Charles River Laboratories International, Inc. executive Joseph W. LaPlume, EVP, Corp Strategy & Develop, reported a bona fide gift of 257 shares of common stock on 2026-08-10. The transaction was a disposition made at a reported per-share price of $0.00, leaving him with 31,041 shares of direct ownership afterward.
Charles River Laboratories International director James C. Foster exercised stock options for 28,733 shares of common stock at an exercise price of $179.66 per share on August 10, 2026 and immediately sold 28,733 shares at $275.00 per share. The options, originally exercisable from May 29, 2021 and expiring May 29, 2030, now show 0 derivative shares remaining from this grant. The exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 6, 2026. Following these transactions, Foster is reported with indirect holdings of common stock through various trusts and GRATs, including 5,423 shares in a 2024 GRAT, 10,780 shares in a 2025 GRAT, and 20,000 shares in a 2026 GRAT.
CRL reports a planned disposition of common stock under a Rule 144 notice. The reporting shareholder, Shannon M. Parisotto, lists 3,714 shares of common stock to be sold for cash on 08/11/2026, with UBS Financial Services, Inc. as broker. The shares are to be issued through an exercise of stock options.
The filing also notes that during the past three months Parisotto sold 5,046 shares of common stock on 08/05/2026 for total proceeds of $1,327,098.00.
Charles River Laboratories International, Inc. senior vice president of finance and chief accounting officer Michael Gunnar Knell reported option exercises and share sales on 2026-08-06. He exercised stock options covering 2,345 shares of common stock at strike prices of $179.66, $194.12, and $208.44 per share and reported open-market sales totaling 6,645 shares of common stock at prices between $258.53 and $265.17 per share, executed in multiple trades at weighted average prices for several tranches.
Charles River Laboratories International, Inc. reported that EVP & Chief People Officer Victoria L. Creamer exercised stock options for 4,179 shares of common stock on 2026-08-06 at an exercise price of $179.66 per share and immediately sold 4,179 shares of common stock at $259.16 per share. The exercised options covered 4,179 shares and now show 0 derivative shares remaining from this grant.
CRL reporting person James Foster filed a notice of proposed sale of common stock. The filing lists a planned sale of 28,733 shares, to be acquired through the exercise of stock options for cash on 08/10/2026. Issuer common shares outstanding are shown as 47,738,872. Over the prior three months, Foster sold 75,000 shares of common stock for an aggregate value of $16,875,000.00.
Charles River Laboratories International, Inc. executive Shannon M. Parisotto, CEVP of Discovery & Safety Assessment, reported a sale of 5,046 shares of common stock at $263.00 per share on August 5, 2026, under a Rule 10b5-1 Trading Plan initially adopted on March 4, 2026. Following the sale, Parisotto directly holds 4,807 shares, and also reports indirect ownership of 9,680 shares held by a trust and 28,510 shares held through Karpathos Investments LLC.
Charles River Laboratories International, Inc. has a planned sale of common stock under Rule 144. The planned sale involves 4,300 shares underlying RSUs and PSUs granted on 01/28/2022 and 2,345 shares from a stock option exercise. The anticipated sale date is 08/06/2026, with transactions routed through UBS Financial Services Inc. and listed on the NYSE.